Last Updated: November 16, 2026

Litigation Details for Mylan Pharmaceuticals Inc. v. Galderma Laboratories Inc. (D. Del. 2010)

« Back to Dashboard


Small Molecule Drugs cited in Mylan Pharmaceuticals Inc. v. Galderma Laboratories Inc.
The small molecule drugs covered by the patents cited in this case are ⤷  Start Trial and ⤷  Start Trial .

Mylan Pharmaceuticals Inc. v. Galderma Laboratories Inc., 1:10-cv-00892: Litigation Summary and Patent Analysis

Last updated: August 25, 2026

Mylan Pharmaceuticals Inc. v. Galderma Laboratories, L.P., No. 1:10-cv-00892, was a Hatch-Waxman patent dispute in the U.S. District Court for the District of Delaware involving Mylan’s proposed generic version of Galderma’s Oracea product, a 40-mg delayed-release doxycycline capsule used to treat inflammatory lesions of rosacea. Mylan challenged Galderma’s patent position after filing an Abbreviated New Drug Application, or ANDA, with a Paragraph IV certification. The matter ended without a reported merits decision addressing patent validity or infringement. The public docket reflects termination by dismissal, and the publicly available record does not disclose the commercial terms of any resolution.[1]

What drug and patents were involved in Mylan v. Galderma?

The dispute concerned Oracea, an oral doxycycline product marketed at a sub-antimicrobial dose. Oracea contains 40 mg of doxycycline, delivered through immediate-release and delayed-release components. Its commercial purpose is to reduce inflammatory activity associated with rosacea without relying on the antibacterial dosing used for infectious disease treatment.[2]

Product and regulatory profile

Item Details
Brand Oracea
Active ingredient Doxycycline
Strength 40 mg
Dosage form Delayed-release capsule
Sponsor Galderma Laboratories, L.P.
FDA approval May 2006
NDA NDA 050805
Primary indication Inflammatory lesions of rosacea
Regulatory pathway New Drug Application
Generic pathway ANDA with Paragraph IV certification

Galderma’s patent estate focused on controlled-release doxycycline compositions and their use in treating rosacea. The principal patents associated with Oracea included U.S. Patent Nos. 7,211,267 and 7,232,572.[3]

Principal Oracea patent families

Patent General subject matter Relevance
U.S. Patent No. 7,211,267 Controlled-release pharmaceutical compositions Covered aspects of the doxycycline delivery system
U.S. Patent No. 7,232,572 Controlled-release doxycycline formulations and related treatment concepts Asserted or implicated in generic-entry disputes
Later continuation patents Formulation and treatment claims Extended protection for selected aspects of the product

The patents were directed less to doxycycline as a molecule and more to dose, release profile, composition, and treatment method. That distinction was important because doxycycline itself was a long-established active pharmaceutical ingredient. Galderma’s exclusivity depended on formulation and method-of-use claims rather than new-molecule protection.

What was the legal posture of Mylan v. Galderma?

Mylan filed the Delaware action after submitting an ANDA for a generic doxycycline product. The case was structured as a Hatch-Waxman patent controversy, with Mylan seeking to clear patent obstacles before commercial launch. Galderma’s patent rights were implicated by Mylan’s Paragraph IV certification.

A Paragraph IV certification states that an Orange Book-listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product. The filing can trigger patent litigation under the Drug Price Competition and Patent Term Restoration Act. A timely patent suit can impose a statutory stay of FDA approval for up to 30 months, subject to court action or earlier resolution.[4]

Procedural timeline

Date Event
2010 Mylan filed the Delaware action against Galderma
2010 Litigation proceeded under Hatch-Waxman procedures concerning Mylan’s ANDA
2011 The action terminated by dismissal
Subsequent years Oracea-related patent disputes continued to affect generic entry and Orange Book protection

The docket does not contain a published claim-construction ruling, summary-judgment decision, or trial judgment establishing that the challenged Oracea patents were valid and infringed. The case therefore provides limited precedent on the substantive merits of Galderma’s patent claims.[1]

Was Mylan v. Galderma a Paragraph IV challenge?

Yes. The case arose from Mylan’s ANDA and its challenge to Galderma’s listed patent rights. The litigation is best characterized as a Paragraph IV Hatch-Waxman action involving a proposed generic version of Oracea.

The practical consequences of the certification were:

  1. Mylan sought FDA approval before expiration of the listed patents.
  2. Galderma obtained the ability to sue for patent infringement before generic launch.
  3. The litigation could delay FDA approval through the statutory 30-month stay.
  4. A dismissal or settlement could preserve Galderma’s market position without a judicial determination on validity.

The public record does not establish that Mylan prevailed on invalidity or non-infringement. It also does not establish that Galderma obtained a final judgment confirming infringement. The case ended without a reported merits resolution.

What was the outcome of the Delaware litigation?

The case was dismissed. No reported opinion in the action provides a final adjudication invalidating the asserted patents, finding non-infringement, or confirming all challenged claims as enforceable.

What does the dismissal mean?

A dismissal in a Hatch-Waxman action can result from several commercial or procedural outcomes, including:

  • A confidential settlement;
  • A license permitting later generic entry;
  • Withdrawal or amendment of the ANDA;
  • A change in the parties’ litigation strategy;
  • A covenant not to sue;
  • Resolution of the dispute through a separate agreement.

The public docket does not disclose the operative commercial terms. Accordingly, the dismissal should not be treated as a finding that Galderma’s patents were either strong or weak. It removed the case from active litigation but did not create a published merits precedent.

What patents protected Oracea after the Mylan case?

Oracea’s protection rested on a combination of formulation patents, treatment patents, and later patent-family activity. The most important early patents were U.S. Patent Nos. 7,211,267 and 7,232,572.

Formulation protection

The formulation claims were commercially significant because they addressed the controlled delivery of doxycycline. Oracea was designed to release doxycycline in a manner supporting a 40-mg daily dose with anti-inflammatory utility. A generic applicant could face infringement risk if its product used substantially similar release characteristics, composition limitations, or dosage architecture.

Formulation patents can create substantial entry barriers even when the active ingredient is old. The relevant questions include:

  • Whether the generic contains both immediate-release and delayed-release portions;
  • Whether the release profile falls within the patent claims;
  • Whether the generic uses the same or an equivalent excipient architecture;
  • Whether the generic labeling directs use for the patented indication;
  • Whether the asserted claims survive written-description, enablement, obviousness, and anticipation challenges.

Method-of-use protection

Oracea’s treatment claims focused on using a low-dose doxycycline regimen to treat rosacea-related inflammatory lesions. Method-of-use claims can be enforced through the generic label, prescribing instructions, and evidence concerning the intended use of the ANDA product.

A generic company may attempt a section viii carve-out for a patented indication under the Hatch-Waxman framework. That strategy is less effective where the patented use is closely tied to the product’s principal commercial indication or where the formulation is itself claimed.

When did Oracea lose exclusivity?

Oracea lost new-drug exclusivity before the principal patent barriers expired. FDA exclusivity and patent exclusivity were separate.

Regulatory exclusivity

Oracea received three-year marketing exclusivity associated with approval of a new clinical application. That period did not provide the long-term protection associated with a new chemical entity. The three-year exclusivity period expired before the later Oracea patent disputes concluded.[2]

Patent exclusivity

The relevant formulation patents extended protection beyond the regulatory exclusivity period. Patent expiration depended on the patent’s effective term, patent-term adjustment, terminal disclaimers, and later continuation patents. The early Oracea patents generally created protection into the early 2020s, subject to the specific patent and claim at issue.

A patent’s expiration date does not automatically produce generic entry. FDA approval timing, litigation settlements, manufacturing readiness, other listed patents, regulatory exclusivity, and court orders can alter the first commercial launch date.

What was the Orange Book status of Oracea?

Oracea was listed in the FDA Orange Book with patent information covering the product’s formulation and use. Orange Book listings provided the basis for Mylan’s Paragraph IV challenge and Galderma’s ability to bring a patent action before generic approval.[5]

The Orange Book should be reviewed by product and patent number because listings can change over time. A product may have:

  • Original formulation patents;
  • Later-issued patents submitted for listing;
  • Method-of-use patents;
  • Delisted patents;
  • Patents with expiration dates modified after patent-term calculations.

The presence of a listed patent does not establish validity or infringement. It identifies a regulatory patent barrier that an ANDA applicant must address.

How strong was Galderma’s patent estate?

Galderma’s Oracea estate had meaningful commercial value but was narrower than a new-molecule estate. Its strength came from the combination of a differentiated dosage form, a specific low-dose regimen, and a treatment indication with a defined clinical market.

Strengths

  • The product used a differentiated delayed-release design.
  • The FDA-approved regimen was tied to the claimed rosacea use.
  • Doxycycline was administered at a dose intended to provide anti-inflammatory rather than conventional antibacterial effects.
  • Formulation and method claims could create overlapping litigation positions.
  • The commercial product and the claimed use were closely aligned.

Vulnerabilities

  • Doxycycline was an established compound.
  • Controlled-release formulation claims could face obviousness attacks based on prior delivery technologies.
  • Method-of-use claims could be vulnerable to label-carve-out strategies.
  • Patent claims had to distinguish the product from prior low-dose doxycycline and modified-release formulations.
  • A generic applicant could design around particular excipients or release mechanisms.

The litigation record does not support a definitive merits rating. The absence of a final opinion means the case should be evaluated as a negotiated-entry dispute rather than as a judicial validation of the Oracea patent estate.

Did Mylan launch a generic Oracea product?

The 2010 Delaware case did not produce a reported immediate generic launch. The case’s dismissal, by itself, does not establish that Mylan obtained an unrestricted launch license or that it was entitled to market immediately.

Generic entry for Oracea depended on:

  • FDA approval of the ANDA;
  • Resolution of the Paragraph IV dispute;
  • Any settlement entry date;
  • Remaining listed patents;
  • Manufacturing and supply readiness;
  • Commercial launch economics.

Later generic doxycycline 40-mg products entered the market after the early Oracea litigation period, but the timing and company-specific rights must be analyzed against the relevant settlement agreements and subsequent patent listings rather than inferred from the 2010 dismissal.

Were biosimilars relevant to this dispute?

No. Oracea is a small-molecule doxycycline product, not a biologic. The relevant competitive pathway was an ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act, not a biosimilar application under the Biologics Price Competition and Innovation Act.

The competitive risks were therefore:

  • Generic substitution;
  • Paragraph IV litigation;
  • Formulation design-around;
  • Label carve-out;
  • Authorized generic strategy;
  • Settlement-controlled entry.

Biosimilar approval, interchangeability, and biologic manufacturing issues were not relevant to this case.

What commercial risks did the litigation create for Galderma?

The principal risk was erosion of Oracea revenue through generic substitution. Because doxycycline was inexpensive as an active ingredient, a successful generic formulation could materially reduce pricing even if the branded product retained physician recognition.

Galderma’s commercial defenses included:

  • Enforcing formulation patents;
  • Enforcing rosacea-use claims;
  • Negotiating a delayed generic-entry date;
  • Maintaining supply and physician loyalty;
  • Using product differentiation based on release technology;
  • Pursuing later patent-family protection.

For Mylan, the upside was first-filer or early-entry economics, while the downside included prolonged litigation, a delayed launch, possible damages exposure, and the cost of developing a formulation that avoided infringement.

How does this case compare with a typical Hatch-Waxman patent trial?

Mylan v. Galderma is commercially important but legally limited because it ended without a reported merits decision. A typical fully litigated Hatch-Waxman case produces a claim-construction ruling, validity decision, infringement judgment, or appeal. This case did not generate that type of precedent.

Its primary significance is procedural and strategic:

  • It shows how an ANDA filer can use a Paragraph IV certification to challenge a branded formulation;
  • It illustrates the importance of controlled-release patents for an old active ingredient;
  • It demonstrates that dismissal can resolve market-entry risk without public disclosure of settlement economics;
  • It confirms that patent listing and patent validity are separate questions.

Key Takeaways

  • Mylan v. Galderma, No. 1:10-cv-00892, was a Delaware Hatch-Waxman dispute concerning a proposed generic version of Oracea.
  • Oracea is a 40-mg delayed-release doxycycline product for rosacea.
  • The principal patent protection centered on controlled-release formulation and rosacea-treatment claims, including U.S. Patent Nos. 7,211,267 and 7,232,572.
  • Mylan’s ANDA included a Paragraph IV challenge to Galderma’s listed patent rights.
  • The case terminated by dismissal without a reported decision on validity or infringement.
  • The public docket does not disclose the terms of any settlement or license.
  • Regulatory exclusivity expired before the principal patent barriers.
  • Biosimilar risk was irrelevant because doxycycline is a small molecule.
  • The case did not itself establish an unrestricted Mylan launch right.
  • Oracea’s patent strength derived from formulation and use protection, not new-chemical-entity protection.

FAQs

What was Mylan challenging in the Oracea patent litigation?

Mylan challenged Galderma’s patent protection for the formulation and use of a 40-mg delayed-release doxycycline product submitted through an ANDA.

Was U.S. Patent No. 7,211,267 invalidated?

No reported decision in Mylan v. Galderma invalidated the patent. The action ended by dismissal without a merits ruling.

Did Galderma sue Mylan for infringing a doxycycline compound patent?

The dispute primarily concerned formulation and treatment protection for Oracea, rather than exclusive ownership of doxycycline as a compound.

Could Mylan use a section viii statement to avoid Oracea patents?

A section viii strategy could address method-of-use claims, but it would not automatically eliminate infringement risk from formulation claims covering the generic product itself.

Did the case establish when generic Oracea could launch?

No. The dismissal did not publicly establish a launch date, license scope, or settlement terms.

References

  1. U.S. District Court for the District of Delaware. (2010-2011). Mylan Pharmaceuticals Inc. v. Galderma Laboratories, L.P., No. 1:10-cv-00892. PACER docket record.

  2. U.S. Food and Drug Administration. (2006). Oracea NDA 050805 approval history and prescribing information. FDA Drugs@FDA.

  3. U.S. Patent and Trademark Office. (2007). U.S. Patent Nos. 7,211,267 and 7,232,572. Patent Center.

  4. U.S. Food and Drug Administration. (2024). ANDA submissions: Paragraph IV certifications and 30-month stays. FDA, Center for Drug Evaluation and Research.

  5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. 44th ed. Orange Book.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.